The quality of life is greatly impacted by respiratory conditions such asthma, interstitial lung disorders, chronic obstructive pulmonary disease (COPD), and acute breathing difficulties, which call for specific pharmaceutical treatments. The need for high-quality, efficient, and reasonably priced respiratory medications that support disease management, increase lung function, and improve patient outcomes is growing in the Indian healthcare system.

A respectable pharmaceutical firm that offers a wide selection of respiratory medications for both acute and chronic respiratory diseases is Steris Healthcare Pvt. Ltd. The respiratory product portfolio, important therapeutic applications, clinical advantages, and the reasons these drugs are regarded as some of the top respiratory medications in India for ailments including asthma, COPD, and other pulmonary diseases are all covered in this comprehensive guide.

About Steris Healthcare Pvt. Ltd.

Steris Healthcare Pvt. Ltd. (often referred to as Steris Pharma) is a WHO-GMP- and ISO-certified Indian pharmaceutical manufacturer committed to delivering high-quality medicines across multiple therapeutic areas, including respiratory, cardiology, gastroenterology, neurology, and more. With a strong focus on quality standards, regulatory compliance, and reliable supply chains, Steris Healthcare supports healthcare professionals, hospitals, and pharmacies with trusted formulations that deliver consistent therapeutic outcomes.

Steris’s commitment to innovation, affordability, and accessibility makes it a preferred partner in the Indian pharmaceutical market, particularly for respiratory care where effective drug therapy can dramatically influence patient well-being and long-term health management.

Understanding the Respiratory Challenges in India

Respiratory diseases, including asthma and COPD, have high prevalence in India due to factors like environmental pollution, smoking, occupational exposure, and genetic susceptibility. These conditions often require long-term management, careful symptom control, and prevention of exacerbations. Effective respiratory therapies must:

• Provide relief from breathing difficulty

• Support long-term disease management

• Reduce acute episodes such as asthma attacks

• Improve quality of life and exercise tolerance

Steris Healthcare’s respiratory range addresses these needs through APIs that support lung function, reduce inflammation, and tackle disease progression.

Core Respiratory Medicines by Steris Healthcare

1. NINTEDONE 150 – Nintedanib (150 mg)

Therapeutic Category: Anti-fibrotic Therapy

Composition: Nintedanib 150 mg per soft gelatin capsule

Key Uses:

• Management of Idiopathic Pulmonary Fibrosis (IPF)

• Slowing disease progression in chronic fibrosing interstitial lung diseases

• Support in systemic sclerosis-associated interstitial lung disease

Clinical Relevance:
Nintedanib is a tyrosine kinase inhibitor that targets growth factor receptors involved in lung tissue scarring. This action helps slow the progression of fibrosis, preserve lung function, and improve respiratory symptoms over time — essential in chronic lung conditions where fibrosis leads to irreversible damage. 

B2B Value:
NINTEDONE 150 is considered among the best respiratory medicines in India for pulmonary fibrosis due to its proven mechanism of action and established clinical outcomes, making it valuable for hospital respiratory departments, pulmonology clinics, and specialty pharmacies.

2. Cynoserine 250 – Cycloserine 250 mg

Therapeutic Category: Respiratory-related Antimicrobial Support

Composition: Cycloserine 250 mg

Key Uses:
While cycloserine’s primary indication is in tuberculosis, its role in respiratory therapy can be supportive in multi-drug regimens where Mycobacterium infections affect lung health.

B2B Value:
For respiratory specialists managing complicated pulmonary infections, including drug-resistant TB protocols, Cynoserine 250 is an important component. It reflects Steris’s dedication to addressing comprehensive respiratory health needs beyond obstructive and inflammatory conditions.

3. SODICHLOR 3% – Sodium Chloride Inhalation Solution USP 3% w/v

Therapeutic Category: Mucolytic / Airway Hydration

Composition: Sodium Chloride 3% w/v for inhalation

Key Uses:

• Hydration of airway secretions

• Adjunct in nebulization therapy to improve mucus clearance

• Supportive therapy in COPD, bronchiectasis, and chronic bronchitis

Clinical Relevance:
A hypertonic saline inhalation solution enhances mucus mobilization, making it easier for patients to clear secretions that contribute to airway obstruction and breathing difficulty. This is especially important for COPD management and bronchiectasis care.

B2B Value:
For respiratory clinics and hospital wards using nebulized therapy, SODICHLOR 3% is an effective, safe, and supportive solution in comprehensive respiratory care protocols.

4. BOSENTIME 62.5 – Bosentan 62.5 mg

Therapeutic Category: Pulmonary Arterial Hypertension (PAH) Support

Composition: Bosentan 62.5 mg tablets

Key Uses:

• Management of pulmonary arterial hypertension

• Improving exercise tolerance and reducing symptoms of breathlessness

Clinical Relevance:
Bosentan is an endothelin receptor antagonist that helps dilate pulmonary blood vessels, reduce pulmonary vascular resistance, and support improved oxygenation in PAH. Patients with PAH often experience severe dyspnea and exercise intolerance; bosentan improves cardiac output and quality of life.

B2B Value:
In specialized respiratory and cardiopulmonary units, BOSENTIME 62.5 provides an essential oral therapy option, aligning with advanced respiratory care strategies.

5. PIRFENOID 400 & PIRFENOID 200 – Pirfenidone (400 mg / 200 mg)

Therapeutic Category: Anti-fibrotic Agent

Composition: Pirfenidone 400 mg / 200 mg tablets

Key Uses:

• Management of idiopathic pulmonary fibrosis

• Slowing lung fibrosis progression

• Symptom control in chronic interstitial lung disease

Clinical Relevance:
Pirfenidone is known for its anti-inflammatory and anti-fibrotic properties, which help inhibit lung tissue scarring and preserve respiratory function in IPF patients. These profiles make the PIRFENOID range highly relevant for clinicians managing long-term fibrotic lung disease.

B2B Value:
Offering multiple strengths (200 mg and 400 mg) allows tailored dosing in clinical regimens, enhancing treatment flexibility and patient compliance.

6. STERIS DPI DEVICE – Dry Powder Inhaler Capsule Device

Therapeutic Category: Drug Delivery Device

Application:

• Facilitates the effective delivery of dry-powder respiratory medications

• Supports asthma and COPD inhalation therapy

Clinical Relevance:
The STERIS DPI Device enables accurate and consistent medication delivery directly into the lungs, enhancing drug action, improving symptom control, and preventing asthma attacks and flare-ups when paired with DPI formulations.

B2B Value:
For hospitals, clinics, and pharmacies, reliable inhalation devices are as crucial as medications in ensuring effective respiratory management.

Respiratory for Management of Asthma and COPD

Asthma and COPD represent two of the most prevalent chronic respiratory disorders in India. Effective management involves:

• Relief from breathing difficulty

• Prevention of asthma attacks

• Long-term maintenance therapy to stabilize lung function

Steris Healthcare’s portfolio, including device support (like the STERIS DPI Device) and inhalation-optimized solutions, supports clinicians in enhancing patient adherence and therapeutic outcomes. The inclusion of mucolytic support (SODICHLOR 3%) and targeted therapies like bosentan further adds depth to treatment protocols.

Clinical Benefits & Patient Outcomes

Steris Healthcare’s respiratory medicines are designed to:

• Support symptom relief and improved respiratory function

• Reduce disease progression in conditions like IPF

• Provide supportive care to manage chronic lung conditions

• Facilitate better drug delivery with inhalation devices

• Enhance quality of life for respiratory patients

Their use across pulmonary clinics, specialty respiratory departments, and corporate hospital settings positions them among the best respiratory medicines in India for both acute and chronic care.

FAQs – Respiratory Medicine Range by Steris Healthcare

Q1. What makes Steris Healthcare’s respiratory range stand out?
Steris offers a broad portfolio spanning anti-fibrotic drugs (e.g., NINTEDONE 150, PIRFENOID), pulmonary circulation support (BOSENTIME 62.5), airway hydration solutions (SODICHLOR 3%), and inhalation devices (STERIS DPI Device), making it one of the best respiratory medicine ranges in India.

Q2. How do these products support COPD management?
Medications like SODICHLOR 3% support mucus clearance, and DPI delivery systems improve drug targeting, enhancing symptom control and reducing exacerbations.

Q3. Are these medicines suitable for chronic respiratory diseases?
Yes. Products like Nintedanib and Pirfenidone are formulated to support long-term management in chronic pulmonary fibrosis and similar conditions.

Q4. Can these medicines help in preventing asthma attacks?
Inhalation devices and targeted formulations improve drug delivery, which, when used in preventive regimens under clinician supervision, contribute to reduced frequency of asthma attacks.

Q5. Are these products compliant with quality standards?
Steris Healthcare’s medicines are manufactured under WHO-GMP and ISO standards, ensuring consistent quality and safety for clinical use.

Conclusion

The Respiratory Range by Steris Healthcare Pvt. Ltd. is a comprehensive, clinically relevant, and high-quality portfolio tailored to address a variety of pulmonary health challenges — from breathing difficulty and COPD management to asthma care and chronic fibrotic lung diseases. With formulations like NINTEDONE 150, PIRFENOID, BOSENTIME 62.5, and supportive solutions such as SODICHLOR 3% and the STERIS DPI Device, this range represents some of the best respiratory medicines in India available for healthcare providers, hospitals, and distributors.